In Reply The goal in writing our article1 was to highlight recent literature to create a conversation around overuse in the field of dermatology, and we appreciate the contributions to that discussion from Chu and colleagues and O’Connor and colleagues. Our review was not intended to be a comprehensive assessment of each topic, nor is it a consensus clinical guideline. Unique clinical scenarios and emerging use criteria (eg, sentinel lymph node biopsy to determine access to treatments instead of prognosis) will influence decisions when treating individual patients. Medical reversal is common, and our view of what constitutes overuse will certainly mature over time.2
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Mostaghimi A, Adamson A, Barbieri J. Evaluation of the Merits and Limitations of Evidence-Based Medicine—Reply. JAMA Dermatol. Published online June 24, 2020. doi:10.1001/jamadermatol.2019.4856
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: